Mostrar el registro sencillo del ítem

Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus

dc.contributor.authorDzyurkevich M.S.
dc.contributor.authorBabkov D.A.
dc.contributor.authorShtyrlin N.V.
dc.contributor.authorMayka O.Y.
dc.contributor.authorIksanova A.G.
dc.contributor.authorVassiliev P.M.
dc.contributor.authorBalakin K.V.
dc.contributor.authorSpasov A.A.
dc.contributor.authorTarasov V.V.
dc.contributor.authorBarreto G.
dc.contributor.authorShtyrlin Y.G.
dc.contributor.authorAliev G.
dc.date.accessioned2020-09-02T22:16:46Z
dc.date.available2020-09-02T22:16:46Z
dc.date.issued2017
dc.identifier10.1038/s41598-017-16405-2
dc.identifier.citation7, 1, -
dc.identifier.issn20452322
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4324
dc.descriptionGlucokinase is one of the promising targets for glucose-lowering agents, and the development of GK activators are now considered as one of the most promising strategies for the treatment of type 2 diabetes mellitus. In this work, a series of novel symmetric molecular constructs, in which two pyridoxine moieties are connected via sulfur-containing linkers, have been synthesized and tested in vitro for glucokinase activation potential. The enzyme activation rates by two most active compounds at 100 μM (~150% and 130%) were comparable to that of the reference agent PF-04937319 (~154%). Both leading compounds demonstrated low cytotoxicity and excellent safety profile in acute toxicity experiment in rats after oral administration with LD50 exceeding 2000 mg/kg of body weight. Binding mode of the active compounds in comparison with the reference agent was studied using molecular docking. The leading compounds represent viable preclinical candidates for the treatment of type 2 diabetes mellitus, as well as a promising starting point for the design of structural analogs with improved activity. © 2017 The Author(s).
dc.language.isoen
dc.publisherNature Publishing Group
dc.titlePyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85034806962.pdf
Tamaño:
2.218Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem